Actemra Shortage: What Providers and Prescribers Need to Know in 2026

The Actemra (tocilizumab) supply crisis of 2021 exposed significant vulnerabilities in biologic medication access for patients with rheumatoid arthritis, giant cell arteritis, and other serious inflammatory conditions. While the acute shortage has resolved and three biosimilars have entered the market, providers in 2026 still face real-world supply challenges, insurance-driven access barriers, and the need for clear patient communication protocols. This guide covers what prescribers need to know to protect continuity of care.

Current Supply Landscape for Tocilizumab Products

As of 2026, four tocilizumab products are FDA-approved and commercially available in the United States:

• Actemra (tocilizumab) — Reference product by Genentech. Available as IV (80 mg, 200 mg, 400 mg vials) and SC (162 mg/0.9 mL prefilled syringe, ACTPen). Supply stable.
• Tofidence (tocilizumab-bavi) — Biogen/Bio-Thera. FDA approved September 2023, launched May 2024. IV formulation only.
• Tyenne (tocilizumab-aazg) — Fresenius Kabi. FDA approved March 2024, launched April 2024. Both IV and SC. Note: ACR reported regional supply constraints for Tyenne in 2025–2026 due to demand.
• Avtozma (tocilizumab-anoh) — Celltrion. FDA approved January 2025. IV launched October 2025; SC available 2026. Full indication parity with Actemra IV, including CRS.

Payer-Driven Access Challenges: Understanding Step Therapy in 2026

The more pressing barrier to Actemra access in 2026 is not supply — it's insurance. The three biosimilar approvals have prompted most major commercial payers to implement step therapy requirements, mandating that patients try a preferred biosimilar before covering brand-name Actemra.

Different payers have different preferred products. For example, some insurers prefer Tyenne and Avtozma; others consider Actemra preferred and Tofidence or Tyenne non-preferred. UnitedHealthcare's 2026 policy designates Actemra and Avtozma as preferred, while Tofidence and Tyenne require documentation of inadequate response to preferred products. Florida Blue requires patients to have tried both Tyenne and Avtozma before covering brand Actemra.

Clinical implications:

• Check your patient's specific payer formulary before prescribing or renewing Actemra
• Document clinical rationale for brand vs. biosimilar before submitting prior authorization
• Keep prior auth documentation current — many payers require reauthorization every 12 months

IV-to-SC Substitution: Clinical Guidance

When IV tocilizumab is unavailable or delayed, substituting the SC formulation is clinically supported. The ACR has endorsed this approach, noting that "when the IV formulation of tocilizumab is not available, we support the substitution of the subcutaneous form in place of the IV formulation with no increased cost to the patient."

Key dosing notes for IV-to-SC conversion (RA indication):

• Patient <100 kg: Start with 162 mg SC every other week, may increase to weekly based on clinical response
• Patient ≥100 kg: 162 mg SC weekly
• GCA indication: 162 mg SC weekly with tapering corticosteroid course; or every other week if clinically appropriate

Note that the SC formulation is not authorized for COVID-19 treatment under the EUA. Also verify that your patient's insurance covers the SC formulation under the pharmacy benefit (rather than medical benefit for IV), as this may affect cost-sharing and prior authorization.

Lab Monitoring: What to Continue During Transitions

Regardless of which tocilizumab product a patient uses, standard monitoring requirements apply. Before initiating or continuing therapy:

• CBC: Do not initiate if ANC <2,000/mm³ or platelet count <100,000/mm³
• LFTs: Hold if AST/AST >1.5x ULN before initiation; manage dose adjustments per label
• Lipids: Monitor at 4–8 weeks after initiation; elevated cholesterol is common
• TB screening: Required before starting; treat latent TB before initiating tocilizumab

39,345+ patients found their medications in stock

39K+

Find Actemra In Stock Today →

Patient Communication Recommendations

When patients face supply barriers, proactive communication prevents panic and delays. Recommended messages to patients:

• Explain that biosimilars are equivalent in efficacy and safety — address common patient concerns about switching brands
• Provide direct contact information for your office and the specialty pharmacy in case of supply disruptions
• Advise patients to use services like medfinder to check real-time pharmacy availability before their dose is due

For a practical guide on helping your patients locate Actemra at pharmacies, see our provider guide to finding Actemra in stock. You can also explore how medfinder for providers can support your practice by helping patients locate medications quickly.